Argenica Clears Second FDA Safety Hurdle Putting US Stroke Trial Within Reach
Two of three FDA-required studies complete as ARG-007 clears genotoxicity hurdle
Argenica Therapeutics (ASX: AGN) has completed the FDA-requested GLP-compliant in vitro Mouse Lymphoma Assay (MLA) for ARG-007, with results confirming no evidence of gene mutation or chromosomal aberrations. This represents the second of three assays required to respond to the FDA clinical hold on the ARG-007 investigational new drug (IND) application. The third and final required study, the GLP hERG cardiac safety assay, is currently in progress. Clearing all three studies is the gateway to conducting the ARG-007 Phase 2b trial in the United States.
Dr Liz Dallimore, Managing Director
“The successful completion of the FDA-requested GLP mouse lymphoma assay is an important step in addressing the clinical hold requirements for ARG-007. The study showed no evidence of gene mutation or chromosomal damage, directly addressing the genotoxicity requirements identified by the FDA. With two of three FDA-requested studies now complete and the hERG assay currently in progress, we are in the final stages of assembling the safety package required for our comprehensive clinical hold response and look forward to updating the market on progress shortly.”
When big ASX news breaks, our subscribers know first
Understanding the FDA clinical hold and why this assay matters
An FDA clinical hold is a formal order that pauses a company from proceeding into human clinical trials until specific safety or regulatory requirements are satisfied. In Argenica’s case, the FDA issued a clinical hold on the ARG-007 IND application and requested three additional studies before the trial could proceed in the United States.
One of those requirements centred on genotoxicity. Before any new drug can be tested in humans, regulators require proof that the compound does not damage DNA. Argenica had already completed two genotoxicity tests for ARG-007, both returning clean results. A third test, using bacterial strains in an Ames assay, produced an inconclusive result — not due to any safety concern, but because ARG-007’s cell-penetrating properties interfered with the bacteria used in the test.
International guidelines specifically provide for this situation and recommend a follow-up test using mammalian cells. The FDA directed Argenica to complete the mouse lymphoma thymidine kinase (TK) assay as the appropriate follow-up.
The MLA uses mouse lymphoma L5178Y cells, which are considerably more tolerant of cationic peptide compounds like ARG-007 than bacterial strains, and more closely reflect the biology of human cells. The assay is also particularly comprehensive: it detects both gene mutations and chromosomal aberrations simultaneously through the “tk” locus system, making it a sensitive, dual-purpose genotoxicity assessment tool in a single study.
Importantly, the FDA specifically named the MLA as an acceptable follow-up assay for ARG-007. This means a clean result directly resolves the genotoxicity component of the clinical hold, rather than leaving it open to interpretation.
The three FDA-required assays and their current status are as follows:
- Tenecteplase (TNK) interaction assay — complete, positive outcome (reported 4 December 2025)
- Mouse Lymphoma Assay (MLA) — complete, no evidence of genotoxicity (reported 21 May 2026)
- GLP hERG cardiac safety assay — currently in progress
Study results and what the science confirms
What the MLA tested and how it was conducted
The study was conducted by Labcorp Early Development Laboratories Ltd (Huntingdon, UK), an internationally accredited GLP laboratory, under full compliance with OECD Guideline 490 and ICH S2(R1). ARG-007 was tested in both the absence and presence of a rat liver metabolising system (S-9), across 3-hour and 24-hour treatment periods, at concentrations up to the maximum achievable level.
Clean result across all test conditions
Across all test conditions, the mutant frequency at every tested concentration of ARG-007 remained below the Global Evaluation Factor (GEF) threshold of 126 mutants per 10⁶ viable cells. The GEF is the regulatory threshold above which a result is considered a positive genotoxicity finding — in simple terms, ARG-007 did not reach the level at which regulators would flag a concern at any concentration tested.
The linear trend test for mutant frequency was non-significant with a negative slope under all three test conditions, providing additional statistical confirmation that there is no dose-dependent increase in mutation frequency attributable to ARG-007.
| Assay | Purpose | Status | Outcome |
|---|---|---|---|
| Tenecteplase (TNK) interaction | Drug-drug interaction safety | Complete | Positive |
| Mouse Lymphoma Assay (MLA) | Genotoxicity (mammalian cell) | Complete | No evidence of genotoxicity |
| GLP hERG cardiac safety | Cardiac channel safety | In progress | Pending |
The next major ASX story will hit our subscribers first
Path to IND reinstatement and Phase 2b trial commencement
Upon completion of the hERG cardiac safety assay, Argenica intends to compile and submit a comprehensive clinical hold response to the FDA as expeditiously as possible. That response will incorporate the results of all three completed assays alongside the updated Phase 2b protocol, which is focused on moderate to severe stroke patients.
Under FDA regulations, the FDA has 30 days from receipt of a complete clinical hold response to advise the sponsor whether the hold has been lifted. A successful outcome would result in the lifting of the clinical hold and approval of the IND, enabling ARG-007 to advance into human clinical trials in the United States. This would represent a significant de-risking milestone for Argenica as a clinical-stage biotechnology company.
In parallel, Argenica is also progressing its Human Research Ethics Committee (HREC) submission to seek approval to establish trial sites in Australia, broadening the geographic scope of the Phase 2b programme.
The key steps on the path forward are:
- Complete GLP hERG cardiac safety assay
- Compile comprehensive FDA clinical hold response (all three assays plus updated Phase 2b protocol)
- Submit response to the FDA
- FDA 30-day review window
- IND reinstatement and Phase 2b trial commencement in the US
- Australian HREC approval process progressing in parallel
Don’t Miss the Next ASX Healthcare Breakthrough
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.